CHENGDU OLYMVAX BIOPHARMACEUTICALS revenue breakdown overview

CHENGDU OLYMVAX BIOPHARMACEUTICALS revenue for the last year amounted to 588.93 M CNY, the most of which — 535.78 M CNY — came from its highest performing source at the moment, Adsorbed Tetanus Vaccine, the year earlier bringing 462.96 M CNY. The greatest contribution to the revenue figure was made by China — last year it brought CHENGDU OLYMVAX BIOPHARMACEUTICALS 588.86 M CNY, and the year before that — 496.12 M CNY.